Physician profile
Albert B Kim
NPI 1851342646
$8,999.79
in general payments reported to CMS, 2019-2025
48 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $1,162 · 2021: $1,620 · 2022: $1,244 · 2023: $1,267 · 2024: $1,262 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705 · Education: $62.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.67 |
| Education | $62.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,344.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,456.28 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.40 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| United Therapeutics Corporation | $593.06 | 2019-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $492.56 | 2019-2025 | |
| Inspire Medical Systems, INC. | $332.44 | 2023-2024 | Inspire |
| Electromed, INC. | $292.59 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $265.32 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $232.02 | 2020-2025 | Opsumit |
| Mylan Specialty L.P. | $173.69 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $141.25 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Insmed, INC. | $133.81 | 2019-2025 | Arikayce |
| Sk Life Science, INC. | $128.57 | 2020-2022 | |
| Boston Scientific Corporation | $115.17 | 2020-2021 | |
| Harmony Biosciences LLC | $115.04 | 2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.